Urine Albumin-to-Creatinine Ratio (UACR) Calculator

About

The Urine Albumin-to-Creatinine Ratio (UACR) is a quantitative laboratory test that measures the amount of albumin excreted in urine relative to urinary creatinine concentration. It is the preferred method for detecting and quantifying albuminuria, replacing the earlier semi-quantitative dipstick method and the less convenient 24-hour urine albumin collection. The test is performed on a random spot urine sample, ideally the first morning void, as this correlates best with 24-hour albumin excretion. UACR corrects for variations in urine concentration by dividing albumin concentration by creatinine concentration, expressed in mg/g or mg/mmol. The clinical utility of UACR was established through landmark epidemiological studies including the Framingham Heart Study and the Kidney Early Evaluation Program, which demonstrated that even mildly elevated UACR (30-300 mg/g, termed microalbuminuria) is a powerful independent predictor of adverse outcomes. UACR is a core component of the KDIGO CKD classification system, which combines GFR (G1-G5) and albuminuria (A1-A3) categories to stratify risk of CKD progression, cardiovascular events, end-stage kidney disease, and mortality. The pathophysiological basis of albuminuria involves disruption of the glomerular filtration barrier — damage to podocytes, the glomerular basement membrane, and endothelial glycocalyx allows albumin to leak into the urinary space. In diabetic nephropathy, albuminuria typically progresses from normal to microalbuminuria to macroalbuminuria, though not all patients follow this trajectory. In hypertensive nephropathy, albuminuria may be more modest. Importantly, a reduction in albuminuria in response to therapy — whether with ACE inhibitors, ARBs, or SGLT2 inhibitors — is associated with improved renal outcomes and is used as a surrogate endpoint in clinical trials. UACR should be monitored regularly in patients with diabetes, hypertension, and established CKD to guide therapy and track disease progression.

Formula

UACR (mg/g) = [Urine Albumin (mg/L) / Urine Creatinine (mg/dL)] × 100

UACR is calculated using a straightforward ratio: UACR (mg/g) = [Urine Albumin (mg/L) / Urine Creatinine (mg/dL)] × 100. The multiplication by 100 is necessary to convert the units: urinary creatinine is measured in mg/dL, but the ratio is expressed as mg of albumin per gram of creatinine. Since 1 dL = 0.1 L and 1 g = 1000 mg, the conversion factor of 100 reconciles these unit differences. For example, if urine albumin is 30 mg/L and urine creatinine is 100 mg/dL, then UACR = (30 / 100) × 100 = 30 mg/g. If urinary creatinine is reported in mmol/L instead of mg/dL, convert to mg/dL first by dividing by 8.84 (since 1 mmol/L of creatinine = 88.4 mg/dL, but the molar mass relationship means 1 mg/dL = 88.4 μmol/L, thus dividing mmol/L by 8.84 gives mg/dL). Alternatively, the SI unit version: UACR (mg/mmol) = Urine Albumin (mg/L) / Urine Creatinine (mmol/L). The conversion between units: 1 mg/g ≈ 0.113 mg/mmol. The ratio approach corrects for urine concentration, which is the key advantage over reporting albumin concentration alone. If a patient is dehydrated (concentrated urine), both albumin and creatinine are proportionally elevated, and the ratio remains relatively stable. Conversely, if a patient is overhydrated (dilute urine), both are proportionally reduced, again preserving the ratio. This concentration correction makes the spot sample reliable without requiring a timed collection. Interpreting the result: UACR <30 mg/g is considered normal (A1 category), 30-300 mg/g indicates microalbuminuria or moderately increased albuminuria (A2), and >300 mg/g indicates macroalbuminuria or severely increased albuminuria (A3). These thresholds are sex-specific when using mg/mmol units: <3.4, 3.4-34, >34 mg/mmol in males; and <4.3, 4.3-43, >43 mg/mmol in females, reflecting slight differences in creatinine excretion between sexes. The normal albumin-to-creatinine ratio varies by age — slightly higher values are considered normal in young children and older adults. Vigorous exercise within 24 hours, acute illness, fever, menstruation, and urinary tract infection can transiently elevate UACR. Confirmation requires repeat testing in the absence of these confounding factors.

Score Interpretation

UACR is a cornerstone of CKD screening, diagnosis, staging, and prognostication as defined by the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Alongside eGFR, UACR forms one of the two axes of the KDIGO heat map that stratifies patients into low, moderately increased, high, and very high risk categories for CKD progression and cardiovascular events. The integration of both markers provides substantially better risk discrimination than either alone. In the general population, the prevalence of albuminuria (UACR ≥30 mg/g) is approximately 7-10% and increases with age, diabetes, hypertension, and obesity. The clinical impact of detecting albuminuria is profound — even low-level albuminuria (UACR 30-300 mg/g) doubles the risk of cardiovascular mortality and increases the risk of progression to end-stage kidney disease by 3-5 fold compared to normoalbuminuria. Higher levels (UACR >300 mg/g) portend even greater risk. Importantly, UACR is modifiable: interventions that reduce albuminuria are associated with improved renal outcomes. The Steno-2 trial in type 1 diabetes and the Action in Diabetes and Vascular Disease trials demonstrated that intensified multifactorial intervention including ACE inhibition reduces albuminuria and prevents progression. More recently, SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) and finerenone (a non-steroidal mineralocorticoid receptor antagonist) have been shown to reduce albuminuria and slow eGFR decline independent of blood pressure and glycemic control. The KDIGO guidelines recommend ACE inhibitors or ARBs as first-line therapy for patients with UACR ≥300 mg/g, with a treatment target of reducing UACR by at least 30% from baseline. For patients with diabetes and UACR 30-300 mg/g, an SGLT2 inhibitor is recommended for renoprotection. Monitoring frequency depends on risk: annually for low-risk individuals, every 3-6 months for those with established albuminuria. UACR should be included as part of routine cardiovascular risk assessment, as it is now incorporated into cardiovascular risk prediction models including the SCORE2 and the American Heart Association pooled cohort equations.

Reference Ranges